Yes, leprosy is curable. A combination of three antibiotics, taken for 6 to 12 months depending on the type of infection, eliminates the bacteria in nearly all patients. The relapse rate after completing treatment is less than 1.1% over nine years, which is low enough that the World Health Organization considers patients “cured” once they finish their course of medication.
That said, “cured” comes with an important caveat: the treatment kills the bacteria and stops the disease from progressing, but it cannot reverse nerve damage that has already occurred. Early diagnosis makes a significant difference in long-term outcomes.
How the Cure Works
The standard treatment is a three-drug regimen known as multidrug therapy, or MDT. It combines three antibiotics that attack the leprosy bacterium from different angles, which prevents the bacteria from developing resistance to any single drug. One of the antibiotics is taken once a month under supervision, while the others are taken daily at home. The entire course is free of charge worldwide through a WHO donation program.
There are two forms of leprosy, classified by how many bacteria are present. The milder form, with fewer bacteria, requires 6 months of treatment. The more severe form, with a higher bacterial load, requires 12 months. Both forms use the same three-drug combination. You stop being contagious as soon as you start the first dose, which means there’s no need for isolation during treatment.
How Effective Is It?
Extremely effective. A WHO study tracking over 70,000 patients found that the cumulative risk of relapse was just 0.77% for the more severe form and 1.07% for the milder form over nine years of follow-up. The three-drug approach is more than 90% more effective at preventing relapse than the older single-drug treatments used before the 1980s. Because most relapses that do occur happen within the first few years after finishing treatment, long-term monitoring isn’t considered necessary. Patients who complete the full course can consider themselves cured.
What Treatment Cannot Fix
Leprosy damages peripheral nerves, which are the nerves that carry sensation to your hands, feet, and face. The antibiotics stop the infection, but they don’t repair nerve fibers that have already been destroyed. Loss of protective sensation, muscle weakness, and visible deformities can persist even after the bacteria are gone. This is why leprosy remains a source of disability for millions of people worldwide, even as the number of active infections drops.
There is some good news on the nerve front. Research has shown that after treatment reduces inflammation, large-scale nerve regeneration can occur, with regrowing nerve fibers persisting for decades in some patients. However, scar tissue in the outermost portions of damaged nerves tends to block those regenerating fibers from reaching their destinations, limiting functional recovery. Short courses of anti-inflammatory steroids can help improve or restore nerve function if the damage is recent, but they’re far less useful for long-standing injuries.
This is the core reason early detection matters so much. Someone diagnosed before significant nerve damage has occurred can be fully cured with no lasting effects. Someone diagnosed late may be bacteriologically cured but left with permanent numbness or weakness that requires lifelong management.
How Leprosy Is Diagnosed
Diagnosis starts with a physical exam. Doctors look for characteristic skin patches that have lost sensation, thickened nerves (often near the elbows or behind the knees), and muscle weakness. A skin biopsy from the edge of an active patch, stained with a special dye, confirms the presence of leprosy bacteria under a microscope. In some cases, skin smears from the earlobes, elbows, and knees can also detect bacteria.
For early or unclear cases, genetic testing (PCR) can detect the bacterium’s DNA in a tissue sample. This doesn’t replace the standard biopsy but can provide supporting evidence when the clinical picture is ambiguous.
Drug Resistance Is Emerging
Resistance to one of the three antibiotics has been reported in several countries where leprosy is still common. This is a concern because that particular drug is the most powerful component of the regimen. Before the three-drug approach was adopted, patients were treated with only one antibiotic for years at a time, and resistance to that drug has been documented since the 1960s. Resistance to the third drug remains rare.
When resistance to the primary antibiotic is detected, a class of backup antibiotics can be substituted. Unfortunately, resistance to those backups has also been reported in some countries, likely because those drugs are widely prescribed for other types of infections. The WHO now recommends active surveillance of drug resistance patterns, particularly in regions with high case numbers.
Leprosy Today
Leprosy has not been eradicated. In 2019, 118 countries reported a combined total of 202,256 new cases, a rate of about 26 cases per million people globally. India, Brazil, and Indonesia account for the vast majority. The WHO’s goal for 2030 is a 70% reduction in new cases detected annually, with 120 countries reporting zero locally acquired infections.
In the United States, roughly 150 to 200 new cases are diagnosed each year, most of them in people who were exposed before immigrating or who had contact with wild armadillos in the southern states (armadillos are a known animal reservoir of the bacterium). Treatment follows the same three-drug protocol and is coordinated through a national program based in Baton Rouge, Louisiana.